Point/counterpoint. Proton therapy is too expensive for the minimal potential improvements in outcome claimed.
Schulz
Robert J
RJ
Yale University, Johnson, Vermont 05656, USA. schulz@pshift.com
Smith
Alfred R
AR
Orton
Colin G
CG
D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D009369:Neoplasms / Q000191:economics* / Q000532:radiotherapy*; D017063:Outcome Assessment, Health Care / Q000191:economics / Q000379:methods; D061766:Proton Therapy; D011882:Radiotherapy, High-Energy / Q000191:economics*; D014481:United States; D011522:Protons
D011522:Protons